[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroimaging\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroimaging":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,80,112,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100632017","efficacy-of-bright-light-therapy-on-cognitive-impairment-in-major-depressive-disorder-and-its-neuroimaging-mechanisms-protocol-for-a-randomised-controlled-trial-100632017",false,"NCT07508215","Efficacy of Bright Light Therapy on Cognitive Impairment in Major Depressive Disorder and Its Neuroimaging Mechanisms: Protocol for a Randomised Controlled Trial","The inclusion and exclusion criteria for MDD patients. 1、Inclusion Criteria:\n\n1. MDD diagnosis according to the Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-Ⅳ), first episode or recurrence, confirmed by an experienced psychiatrist using the Mini International Neuropsychiatric Interview.\n2. Age between 18 and 60 years; and gender no-limited;\n3. The severity of MDD symptoms must be ≥14 scores on the HAMD-17;\n4. With CI currently, defined as a total score of \\\u003C70 on the SC;\n5. A SSRI monotherapy at stable dosages for at least 4 weeks; or medication-free status;\n6. Education level above primary school, able to understand and cooperate in completing the study procedures;\n7. Voluntarily participating in this study and sign the informed consent before enrollment.\n\n2、Exclusion Criteria:\n\n1. Current or past diagnosis of any disorder other than MDD according to DSM-Ⅳ criteria;\n2. The scores on the Young Mania Rating Scale (YMRS) are\\>8;\n3. The participants who have undergone other intervention in addition to SSRIs whinin the past 6 months or now, or who plan to do that in 1 month;\n4. The participants with strong self-blame, self-harm, or suicidal risks (the HAMD-17 suicide item score of ≥3);\n5. The participants with severe physical illnesses, including heart failure, renal failure, severe liver dysfunction, hyperthyroidism, or hypothyroidism; Or a history of severe brain trauma or organic brain pathology (e.g., intracerebral hemorrhage, large-area cerebral infarction, encephalitis, epilepsy), as well as neurological diseases;\n6. The participants with any degree of retinal pathology, including retinal dystrophy, age-related macular degeneration, diabetic retinopathy, cataracts, glaucoma, or other ocular diseases;\n7. The participants with photosensitive conditions, such as systemic lupus erythematosus, porphyria, chronic photodermatitis, solar urticaria, or those currently receiving medications that may increase photosensitivity (e.g., phenothiazines, antimalarials, propranolol, hypericin, stimulants, or chronic treatment with nonsteroidal anti-inflammatory drugs);\n8. Pregnant or lactating women;\n9. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia;\n10. The participants deem unsuitable for inclusion in this study by the investigator for other reasons.\n\nWithdrawal and Termination Criteria：\n\n1. The participants meet one of the exclusion criteria above after enrollment;\n2. When the participants' treatment regimen need change;\n3. The participants who fail to cooperate or voluntarily withdraw from the study;\n4. Due to severe adverse events, the patients are unable to tolerate phototherapy;\n5. The participants who fail to adhere to the study protocol intervention for three consecutive days or for a cumulative duration exceeding seven days;\n6. Cancellation of the study.\n\nThe inclusion and exclusion criteria for Health controls\n\n1\\. Inclusion criteria\n\n1. Age between 18 and 60 years; and gender no-limited;\n2. Without CI currently, defined as a total score of ≤ 70 on the SC;\n3. Education level above primary school, able to understand and cooperate in completing the study procedures;\n4. Voluntarily participating in this study and sign the informed consent before enrollment.\n\n2.Exclusion criteria\n\n1. Current or past diagnosis of any psychiatric disorders, or history of substance\u002Fdrug abuse or dependence;\n2. Current or past diagnosis of severe somatic diseases, such as heart failure, renal failure, severe liver dysfunction, or hyperthyroidism\u002Fhypothyroidism;\n3. History of severe traumatic brain injury or organic brain lesions;\n4. Pregnant or lactating women;\n5. The participants with contraindications to MRI, such as the presence of non-MRI-safe metallic implants or claustrophobia.\n6. The participants deem unsuitable for inclusion in this study by the investigator for other reasons.",true,"ALL","18 Years","60 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to validate the therapeutic efficacy and safety of bright light therapy (BLT) in ameliorating cognitive impairment (CI) in major depressive disorder (MDD), characterize the functional and structural features of the hippocampus (HPC)-dorsolateral prefrontal cortex (dlPFC) neural circuitry in MDD participants with CI and examine the mediating effect of the HPC-dlPFC neural circuit on CI induced by BLT treatment in MDD participants. MDD participants will be required to only receive selective serotonin reuptake inhibitors (SSRIs) as monotherapy for at least four weeks, or medication-free status before enrollment. Eligible participants will be randomly assigned to the experimental group and the control group. The experimental group will receive the intervention of BLT, and the control group will receive the intervention of dim red light (DRL). The intervention will last for four weeks, 6 days per week, with 40 minutes each day between 7 am and 10 am. The MDD participants will be followed once in the end of each week during the 4-week intervention and in the end of the 4th week after intervention. Demographic information will be collected at baseline; cognitive function will be evaluated at baseline, weeks 2, 4, and 8 after intervention beginning; and other symptoms such as depression, anxiety and sleep were assessed at baseline, weeks 1, 2, 3, 4, and 8 after intervention beginning. Moreover, structural and functional MRI scans will be made at baseline and post-intervention. During the intervention, MDD participants will be required to keep a record of daily light exposure duration and complete the daily sleep diary as well.",[27,28,29,30],"Major Depressive Disorder (MDD)","Neuroimaging","Bright Light Treatment","Cognitive Impairment",[32,28,33,34,30,35],"Major Depressive Disorder","Magnetic Response Imaging","Bright Light Therapy","Randomized Controlled Trial","RECRUITING","2026-06-28",{"date":39,"type":40},"2026-06-30","ACTUAL",{"date":42,"type":40},"2026-02-08",{"date":44,"type":21},"2028-12-31",{"name":46,"class":47},"Peking University Sixth Hospital","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":15,"sex":16,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100473460","investigating-the-neural-correlates-of-cognitive-function-in-psychosis-patients-and-non-psychiatric-controls-with-cannabis-use-100473460","NCT05445180","Investigating the Neural Correlates of Cognitive Function in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Investigating the Neural Correlates of Cognitive Function Associated With Cannabis Abstinence in Psychosis Patients and Non-Psychiatric Controls With Cannabis Use","Inclusion Criteria:\n\n* Able to provide informed consent in English or French\n* Heavy cannabis use (defined as weekly cannabis use for at six months) and\u002For DSM-5 diagnosis of CUD\n* Have a Full-Scale IQ ≥ 75\n* Meet DSM-5 criteria for a psychotic disorder (psychosis patient arm only)\n* Be an outpatient receiving a stable dose of medication(s) for at least two months (psychosis patient arm only)\n* Clinically stable (as measured by the PANSS-6, total score \\\u003C30) (psychosis patient arm only)\n\nExclusion Criteria:\n\n* current SUD (other than CUD)\n* MRI contraindications\n* Positive urine screen for psychoactive substances other than cannabis, nicotine, or caffeine\n* Current suicidal or homicidal ideation\n* Head injury requiring hospitalization or loss of consciousness \\> 5 minutes\n* Current medical diseases that requires hospitalization or regular monitoring\n* Being pregnant\n* DSM-5 Axis 1 diagnosis (other than CUD) (non-psychiatric controls only)\n* Taking psychotropic medication","16 Years","80 Years",{"count":59,"type":21},134,[24],"Cognitive impairment is well established in people with psychosis and is associated with cannabis use. The current study will investigate the neurobiological basis of cognitive change associated with 28-days of cannabis abstinence in people with psychosis and non-psychiatric controls with cannabis use. Participants will be randomized to a cannabis abstinent group or a non-abstinent control group and will undergo magnetic resonance imaging at baseline and following 28-days of abstinence. This study will help characterize the neuropathophysiological processes underlying cognitive dysfunction associated with cannabis use and its recovery which may guide the development of novel interventions for problematic cannabis use.",[63,64,65,66,67,68,69,28],"Psychotic Disorders","Cannabis Use Disorder","Cannabis Dependence","Cannabis Use","Schizophrenia; Psychosis","Cognitive Dysfunction","Memory Impairment","2026-05-19",{"date":72,"type":40},"2026-05-22",{"date":74,"type":40},"2022-04-21",{"date":76,"type":21},"2027-05",{"name":78,"class":47},"Douglas Mental Health University Institute",1,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":89,"briefSummary":90,"conditions":91,"keywords":96,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100489612","ifd-survive-functional-efficacy-and-biological-correlates-reconcile-study-100489612","NCT05655390","iFD-SuRvivE funCtiONal effiCacy and bIologicaL corrElates (RECONCILE Study)","The SURVIVE 2 Project: An Extended Cohort Study to Investigate Suicidal Behavior in Spain and the Efficacy of Secondary Prevention Strategies: iFD-SuRvivE funCtiONal effiCacy and bIologicaL corrElates (RECONCILE Study)","RECONCILE","Inclusion Criteria:\n\n* Age over 18 years old\n* Having attempted suicide\n* Provide written informed consent\n* No claustrophobia\u002Fmetallic objects\u002Fimplants\n\nExclusion Criteria:\n\n* Intelligence quotient below 70 and impaired functioning\n* Any medical condition that could affect neuropsychological performance (such as neurological diseases) or a history of head trauma with loss of consciousness\n* Participation in any structured psychological intervention within the past 6 months\n* Patients who received electroconvulsive therapy within the past 6 months\n* Inability to give inform consent",{"count":20,"type":21},[24],"The goal of this clinical trial is to assess the effectiveness of an original intervention 'Functional Recovery in Depression and Suicide Risk Prevention Based on Emotion Regulation and Values: A Group Program' (from the original Spanish version: Programa Grupal De Recuperación Funcional En Depresión Y Prevención De Riesgo Suicida Basado En Regulación Emocional Y Valores) in depressed patients who have recently attempted suicide by improving their psychosocial functioning and therefore enhancing their ability to perform activities of daily living. As secondary objectives, the effectiveness of the intervention will be evaluated by determining cognitive performance (particularly decision-making, inhibition, and attention), quality of life, clinical status, and their relationship with neuroimaging correlates. Main target neuroimaging areas include the orbitofrontal cortex and dorsal prefrontal cortex.",[92,93,94,28,95],"Suicide, Attempted","Functioning, Psychosocial","Cognition","Quality of Lifte",[97,98,99,100,101],"suicide","cognition","neuroimaging","psychosocial functioning","quality of life","2026-05-08",{"date":104,"type":40},"2026-05-12",{"date":106,"type":40},"2025-09-16",{"date":108,"type":21},"2027-10",{"name":110,"class":47},"Iria Grande",4,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":15,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":79},"100424742","modeling-the-effects-of-chronic-marijuana-use-on-neuroinflammation-and-hiv-related-neuronal-injury-100424742","NCT04810858","Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury","CHI","Inclusion Criteria:\n\n* verified HIV status\n* Current marijuana use (MJ+ groups only)\n* No current marijuana use (MJ- groups only)\n* current engagement in HIV care (HIV+ participants only)\n* receipt of cART as first-line of treatment (HIV+ participants only)\n* stable cART regimen (HIV+ participants only)\n* undetectable HIV RNA viral load for \\>1 year (HIV+ participants only)\n\nExclusion Criteria:\n\n* Lifetime abuse for any illicit drug other than marijuana\n* \\\u003C9th grade education; illiteracy or lack of fluency in English\n* history of moderate or severe head trauma\n* unstable or serious neurological disorders\n* severe mental illness\n* systemic autoimmune diseases\n* immunotherapy\n* MRI contraindications","25 Years","59 Years",{"count":122,"type":21},220,[24],"This study applies a hypothesis-driven approach to examine the effects of chronic marijuana use on HIV-associated inflammation and its subsequent impacts on central nervous system function, with the goal of identifying the mechanisms through which cannabinoids modulate neurological disorders and other comorbidities in persons with HIV.",[126,127,128,94,28],"Cannabis","HIV","Inflammation","2026-03-27",{"date":131,"type":40},"2026-03-31",{"date":133,"type":40},"2021-08-18",{"date":135,"type":21},"2027-05-31",{"name":137,"class":47},"Wake Forest University Health Sciences",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":15,"sex":16,"minAge":145,"maxAge":4,"enrollmentInfo":146,"targetDuration":4,"studyType":22,"phases":148,"briefSummary":149,"conditions":150,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":79},"100597159","rural-autistic-individuals---supporting-expression-100597159","NCT07054866","Rural Autistic Individuals - Supporting Expression","RAISE","Inclusion Criteria:\n\n* 1.1 Confirmed (preferably) or suspected diagnosis of ASD (autism spectrum disorder), or a receptive language impairment (i.e., difficulties with comprehension, Developmental Language Disorder), or both. Additional diagnoses, including ADHD (Attention Deficit and Hyperactivity Disorder), are acceptable. Siblings and cousins of these individuals are also welcome.\n\nOR 1.2 No diagnoses of ASD or DLD for unrelated control typically-developing participants.\n\n2\\. Normal hearing and normal vision (or corrected to normal with glasses or contacts).\n\n3\\. Ages 2+. 4. English as the dominant language of caregivers. 5. Caregivers who self-identify as living in a rural area. 6. The ability to verbally or physically respond is optional.\n\nExclusion Criteria:\n\n* 1\\. Poor hearing. 2. Inborn or acquired brain damage.","2 Years",{"count":147,"type":21},50,[24],"This research study investigates how hand gestures can support language comprehension and communication skills of hearing speaking, non-speaking, and\u002For minimally verbal individuals with Autism Spectrum Disorders (ASD), who are especially disadvantaged by the lack of accessible services in their rural communities. Individuals with other cognitive profiles, including Developmental Language Disorder (DLD), ADHD, Dyslexia, and others are welcome too. The study uses methods of eye tracking and recording of brain activity to understand how hand gestures adapted from signs from American Sign Language, such as \\[cry\\], can promote successful understanding of words like \"cry\". The overarching goal is to help families effectively utilize gestures to support communication with their children.",[151,152,153,154,155,156,28,157,158,159],"Autism Disorder","Language Development Disorders","ADHD","Typical Development","Rural Health","Children","Eye Tracking","EEG","fNIRS","2025-07-07",{"date":162,"type":40},"2025-07-10",{"date":164,"type":21},"2025-07",{"date":166,"type":21},"2027-07",{"name":168,"class":47},"Montana State University"]